Open Payments

Cpmc - Mission Bernal Campus

Type
Teaching hospital
Where
San Francisco, CA
Medicare CCN
050055
Received
$366,232 in 34 records, 2024 ($0 general, $366,232 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2024Research payment34$366,232

By company

CompanyRecordsAmountYears
Edwards Lifesciences Corporation21$279,8212024
Intercept Pharma Europe Ltd.3$43,8702024
E.R. Squibb & Sons, L.L.C.3$19,9812024
Mirati Therapeutics, Inc.2$12,9742024
Incyte Corporation2$7,3352024
Celgene Corporation3$2,2502024

By nature of payment

NatureRecordsAmount
Research payment34$366,232

Records

DateCompanyAmountNatureFormProductStudyYear
2024-12-12Edwards Lifesciences Corporation$14,526Research paymentCash or cash equivalentPartner3 2015-082024
2024-12-09Edwards Lifesciences Corporation$1,815Research paymentCash or cash equivalentALLIANCE 2021-052024
2024-12-05Edwards Lifesciences Corporation$9,994Research paymentCash or cash equivalentThe PROGRESS Trial – Continued Access 2021-01-CAP2024
2024-11-23Edwards Lifesciences Corporation$2,474Research paymentCash or cash equivalentCLASP IID 2018-072024
2024-11-04Edwards Lifesciences Corporation$37,760Research paymentCash or cash equivalentTHE ENCIRCLE Trial (#2018-19)2024
2024-11-04Edwards Lifesciences Corporation$796Research paymentCash or cash equivalentSM3 Trial 2017-032024
2024-11-01Mirati Therapeutics, Inc.$955Research paymentCash or cash equivalentKRAZATI Drug, OncologyA Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colore2024
2024-09-26Intercept Pharma Europe Ltd.$26,855Research paymentCash or cash equivalentOCALIVA Drug, Hepatology / GastroenterologyRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2024
2024-09-12Edwards Lifesciences Corporation$40,216Research paymentCash or cash equivalentTHE ENCIRCLE Trial (#2018-19)2024
2024-09-12Edwards Lifesciences Corporation$19,872Research paymentCash or cash equivalentALLIANCE 2021-052024
2024-09-12Edwards Lifesciences Corporation$4,138Research paymentCash or cash equivalentPartner3 2015-082024
2024-09-11Celgene Corporation$1,500Research paymentCash or cash equivalentREBLOZYL Biological, HematologyCelgene Connect Myeloid Disease Registry2024
2024-08-29Edwards Lifesciences Corporation$9,450Research paymentCash or cash equivalentThe PROGRESS Trial – Continued Access 2021-01-CAP2024
2024-07-25Intercept Pharma Europe Ltd.$3,000Research paymentCash or cash equivalentOCALIVA Drug, Hepatology / GastroenterologyRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2024
2024-07-18Intercept Pharma Europe Ltd.$14,014Research paymentCash or cash equivalentOCALIVA Drug, Hepatology / GastroenterologyRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2024
2024-06-24Edwards Lifesciences Corporation$14,850Research paymentCash or cash equivalentALLIANCE AVIV 2021-052024
2024-06-06Edwards Lifesciences Corporation$14,327Research paymentCash or cash equivalentThe PROGRESS Trial 2021-012024
2024-05-28Edwards Lifesciences Corporation$4,595Research paymentCash or cash equivalentALLIANCE 2021-052024
2024-05-24Mirati Therapeutics, Inc.$12,018Research paymentCash or cash equivalentA Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colore2024
2024-05-15Celgene Corporation$375Research paymentCash or cash equivalentRevlimid Drug, HematologyThe purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and treatment2024
2024-05-13Edwards Lifesciences Corporation$20,493Research paymentCash or cash equivalentEarly-TAVR Trial #2016-072024
2024-05-09Edwards Lifesciences Corporation$30,144Research paymentCash or cash equivalentTHE ENCIRCLE Trial (#2018-19)2024
2024-05-09Edwards Lifesciences Corporation$3,476Research paymentCash or cash equivalentSM3 Trial 2017-032024
2024-04-24E.R. Squibb & Sons, L.L.C.$1,650Research paymentCash or cash equivalentOPDIVO Biological, OncologyPhase III Adjuvant HCC (mono vs placebo)2024
2024-03-25Edwards Lifesciences Corporation$3,422Research paymentCash or cash equivalentSM3 Trial 2017-032024
2024-03-07Incyte Corporation$3,885Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo2024
2024-02-29Edwards Lifesciences Corporation$8,953Research paymentCash or cash equivalentEarly-TAVR Trial #2016-072024
2024-02-26Edwards Lifesciences Corporation$3,727Research paymentCash or cash equivalentPartner3 2015-082024
2024-02-16E.R. Squibb & Sons, L.L.C.$15,172Research paymentCash or cash equivalentPhIII Stage 3/4 Resectable Mel Adj Rela+Nivo vs Nivo - A Phase 3, Randomized, Double-blind Study of Adjuvant Immunothera2024
2024-02-01Edwards Lifesciences Corporation$21,353Research paymentCash or cash equivalentTHE ENCIRCLE Trial (#2018-19)2024
2024-02-01Edwards Lifesciences Corporation$13,433Research paymentCash or cash equivalentALLIANCE 2021-052024
2024-01-31Celgene Corporation$375Research paymentCash or cash equivalentRevlimid Drug, HematologyThe purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and treatment2024
2024-01-22E.R. Squibb & Sons, L.L.C.$3,159Research paymentCash or cash equivalentOPDIVO Biological, OncologyPhase III Adjuvant Melanoma Stage II B/C Opdivo Mono2024
2024-01-18Incyte Corporation$3,450Research paymentCash or cash equivalentA Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants2024

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

San Francisco CountySan Francisco city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.

MeasurePlace (city or town)
San Francisco, CA
County
San Francisco County, CA
State
California
Population B01003830,235830,23539,287,377
Population, 2020 census P1873,965873,96539,538,223
Median age B0100240.040.037.9
Under 18 B0100113.7%13.7%22.0%
65 and over B0100117.6%17.6%15.7%
Households B11001363,970363,97013,548,091
Foreign born B0500234.0%34.0%27.0%
Median household income B19013$140,970$140,970$99,122
Median family income B19113$171,141$171,141$113,346
Per capita income B19301$92,289$92,289$49,513
Poverty rate B1700111.2%11.2%12.0%
Unemployment rate B230256.1%6.1%6.6%
Civilian labor force B23025507,262507,26220,068,466
Mean commute (minutes) B0801330.430.428.7
Bachelor's degree or higher B1500360.3%60.3%37.1%
Housing units B25001414,602414,60214,644,735
Owner-occupied B2500338.2%38.2%55.9%
Renters B2500361.8%61.8%44.1%
Median home value B25077$1,394,500$1,394,500$734,700
Median gross rent B25064$2,476$2,476$2,036
White, not Hispanic B0300236.8%36.8%33.8%
Black B030024.7%4.7%5.2%
Hispanic or Latino B0300216.2%16.2%40.2%
Asian B0300234.9%34.9%15.3%
American Indian and Alaska Native B030020.2%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.